Exposure to acellular blood products and risk of HIV infection in hemophiliacs from Belo Horizonte, Brazil.
Results of a HIV prevalence study conducted in hemophiliacs from Belo Horizonte, Brazil are presented. History of exposure to acellular blood components was determined for the five year period prior to entry in the study, which occurred during 1986 and 1987. Patients with coagulations disorders (hemophilia A = 132, hemophilia B = 16 and coagulation disorders other than hemophilia = 16) were transfused with liquid cryoprecipitate, locally produced, lyophilized cryoprecipitate, imported from São Paulo (Brazil) and factor VIII and IX, imported from Rio de Janeiro (Brazil), Europe, and United States. Thirty six (22%) tested HIV seropositive. The univariate and multivariate analysis (logistic model) demonstrated that the risk of HIV infection during the study period was associated with the total units of acellular blood components transfused. In addition, the proportional contribution of the individual components to the total acellular units transfused, namely a increase in factor VIII/IX and lyophilized cryoprecipitate proportions, were found to be associated with HIV seropositivity. This analysis suggest that not only the total amount of units was an important determinant of HIV infection, but that the risk was also associated with the specific component of blood transfused.
Proietti
F A
FA
Dep. Propedêutica Complementar, Universidade Federal de Minas Gerais, Brazil.
Proietti
A B
AB
Costa
M F
MF
Antunes
C M
CM
Guimarães
M D
MD
Paulino
U H
UH
Souza
C J
CJ
Melo
L
L
Muñoz
A
A
D000293:Adolescent; D000328:Adult; D001778:Blood Coagulation Disorders / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D001938:Brazil / Q000453:epidemiology; D005164:Factor IX / Q000009:adverse effects*; D005169:Factor VIII / Q000009:adverse effects*; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000453:epidemiology* / Q000209:etiology / Q000276:immunology; D015528:HIV Seroprevalence; D015497:HIV-1; D006467:Hemophilia A / Q000150:complications / Q000453:epidemiology* / Q000276:immunology / Q000628:therapy; D006801:Humans; D016015:Logistic Models; D008297:Male; D012307:Risk Factors; D065227:Transfusion Reaction; D014505:Urban Population / Q000706:statistics & numerical data*
D015483:HIV Antibodies; D005169:Factor VIII; D005164:Factor IX